About Us

Our mission: to help people living with Parkinson’s to live well today.


Support Us

Generics to hit sales growth for Parkinson’s drugs

LYNNE TAYLOR, www.pharmatimes.com

Sales of drugs to treat Parkinson’s disease in seven major markets will decline slightly, from a total $2.7 billion in 2010 to $2.6 billion in 2020, as key treatments lose patent protection, say new forecasts.

The major therapies on which patents are set to expire by 2020 are Novartis/Orion Pharma’s Comtan/Comtess/Stalevo (carbidopa/levodopa/entacapone) and Teva/Lundbeck’s Azilect/Agilect (rasagiline), according to the study, from Decision Resources.

Also facing increasing generic competition will be ropinirole (GlaxoSmithKline’s Requip and GSK/SkyePharma’s Requip XL/LP/RP/Modutab/Prolib) and pramipexole (Boehringer Ingelheim’s Mirapex/Mirapexin/Sifrol/BI-Sifrol and Mirapex ER/Mirapexin ER/Sifrol Retard), it adds. Click here to read the rest of the article.

This entry was posted in Blog, News. Bookmark the permalink.